Seminar on the topic: Technology-Enabled Advances in Disease Detection, Evaluation, and Management

At 2:00 p.m. on November 14, 2025, IAST organized a session at Room 604, Office of the IAST at Hanoi (99 Tran Quoc Toan, Cua Nam, Hanoi) with the following details:

1/ Dr. La Thi Huyen reported on the topic: Development and Application of a CAFLUX HepG2 Reporter Cell Line for Real-Time Monitoring of AhR-Mediated CYP1A1 Gene Expression in Response to Environmental Toxicants and Bioactive Modulators

Abstract:

This study reports the construction and validation of a CAFLUX (Chemically Activated Fluorescent Expression) HepG2 reporter cell line engineered to express a histone H2B–GFP fusion protein under the control of a dioxin-responsive CYP1A1 promoter. A lentiviral construct containing a synthetic promoter with multiple dioxin-responsive elements (DREs) upstream of the H2B–EGFP coding sequence was cloned into the pFUGW vector, packaged in HEK 293FT cells, and used to transduce HepG2 cells. Sta-ble clones obtained by limiting dilution were screened for GFP expression in response to TCDD. The resulting CAFLUX HepG2 cells exhibit dose-dependent nuclear GFP fluorescence when exposed to AhR agonists, with limits of detection of approximately 0.01 pM for TCDD and 0.1 pM for benzo[a]pyrene (B[a]P). This reporter activity cor-related with endogenous CYP1A1 mRNA expression as determined by quantitative PCR, confirmed that GFP signals reflected native transcriptional responses. In functional assays, curcumin suppressed GFP expression in a concentration-dependent manner and induced apoptotic morphology at higher doses, while extracellular vesi-cles (EVs) derived from adipose-derived stem cells significantly reduced both GFP flu-orescence and CYP1A1 mRNA levels, suggesting an inhibitory effect on AhR-driven transcription. The CAFLUX HepG2 reporter system therefore provides a sensitive and reproducible platform for real-time, nuclear-localized monitoring of AhR-mediated gene expression. Its responses to both agonists and antagonists underscores its potential utility in toxicological evaluation, drug discovery, and the investigation of EV-mediated signaling in liver cancer models.

2/ Dr. Nguyen Hoang Long reports on the topic: Artificial Intelligence in Alzheimer's Disease: From Early Detection to Personalized Care

Abstract: 

Alzheimer's disease (AD) remains one of the most challenging neurodegenerative disorders, characterized by progressive cognitive decline and complex pathophysiology. Recent advances in artificial intelligence (AI) have opened new opportunities to improve the early diagnosis, prognosis, and management of AD. This presentation provides an overview of AI applications across the Alzheimer's disease continuum. Machine learning and deep learning algorithms have demonstrated high accuracy in detecting subtle brain changes on neuroimaging, predicting conversion from mild cognitive impairment to AD, and analyzing multimodal data including genetics, biomarkers, and speech patterns.
Moreover, AI-powered tools are increasingly used to monitor patient behavior, cognitive performance, and medication adherence through wearable sensors and mobile platforms, enabling personalized interventions and supporting caregivers. Despite these achievements, challenges remain in data heterogeneity, interpretability, ethical use, and integration into clinical workflows. The presentation highlights current evidence, emerging innovations, and future directions toward the responsible and effective implementation of AI to improve Alzheimer's care.